[Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid].

Abstract

PURPOSE:

We study the efficacy of treating ocular cicatricial pemphigoid (OCP) with subconjuctival mitomycin C (MMC).

METHODS:

The patients were eligible for treatment under two criteria: 1. Significant complications of systemic immunosuppressant therapy. 2. Avanced stage of OCP. All patients received an injection of 0.25 ml of 0.2 mg/ml mitomycin C to both the upper and lower bulbar conjunctiva in both eyes.

RESULTS:

Four patients were treated with subconjunctival mitomycin C (both eyes) and were followed for an average of 17 months (range 9-26 months). Three of four patients showed progression of the conjunctival disease and required concomitant systemic immunosuppressive therapy after subconjuctival mitomycin C.

CONCLUSION:

No complications of subconjunctival mitomycin C treatment were noted but, contrary to what other authors had referred, its use was not effective in preventing progression of conjunctival cicatrization in our patients with OCP.

• Authors: J Celis Sánchez, N López Ferrando, M García Largacha, F González del Valle, M J Ortiz de la Torre
• Journal: Archivos de la Sociedad Espanola de Oftalmologia (Arch Soc Esp Oftalmol) Vol. 77 Issue 9 Pg. 501-6 (Sep 2002) ISSN: 0365-6691 [Print] Spain
• Vernacular Title: Mitomicina C subconjuntival en el tratamiento del penfigoide ocular cicatricial.
• PMID: 12221542 (Publication Type: English Abstract, Journal Article)

Chemical References

• Immunosuppressive Agents
• Nucleic Acid Synthesis Inhibitors
• Ophthalmic Solutions
• Mitomycin

Topics

• Aged
• Aged, 80 and over
• Autoimmune Diseases (complications, drug therapy)
• Disease Progression
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Fluorescent Antibody Technique, Direct
• Follow-Up Studies
• Glaucoma (complications)
• Humans
• Immunosuppressive Agents (administration & dosage, therapeutic use)
• Injections
• Male
• Mitomycin (administration & dosage, therapeutic use)
• Nucleic Acid Synthesis Inhibitors (administration & dosage, therapeutic use)
• Ophthalmic Solutions (administration & dosage, therapeutic use)
• Pemphigoid, Benign Mucous Membrane (complications, drug therapy)
• Treatment Failure